Aera Therapeutics utilizes a protein nanoparticle (PNP) delivery platform that self-assembles from endogenous human proteins to package and transfer nucleic acid cargo. This technology addresses the limitations of current delivery methods for genetic medicines, enabling broader therapeutic applications.
Funding
$247M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current delivery methods for genetic medicines have limitations that restrict their therapeutic applications. These limitations hinder the broad application of genetic medicines across various modalities and therapeutic areas.
Solution
Aera Therapeutics has developed a protein nanoparticle (PNP) delivery platform that utilizes endogenous human proteins capable of self-assembling into capsid-like structures. This platform packages and transfers nucleic acid cargo, addressing many of the limitations associated with existing delivery technologies. By leveraging these self-assembling proteins, Aera's technology aims to enable a wider range of genetic medicine modalities. The platform is designed to improve the delivery of genetic medicines, potentially transforming the treatment of human diseases.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing and delivering genetic medicines across a broad range of therapeutic areas.
Features
- Protein nanoparticle (PNP) delivery platform
- Self-assembling capsid-like structures formed from endogenous human proteins
- Capability to package and transfer nucleic acid cargo
- Designed to overcome limitations of current genetic medicine delivery technologies
- Potential to enable various genetic medicine modalities